

Effects of "Restrictive" and "Liberal" strategies of intra-operative fluid management during optimisation of oxygen delivery in high-risk surgical patients

Submission date 02/07/2007	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 27/09/2007	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 31/12/2020	Condition category Surgery	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof Suzana Lobo

Contact details
Av Faria Lima 5544
School of Medicine - Intensive Care
São José do Rio Preto
Brazil
15090-000

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

Study information

Scientific Title

Effects of "Restrictive" and "Liberal" strategies of intra-operative fluid management during optimisation of oxygen delivery in high-risk surgical patients

Acronym

RxL

Study objectives

"Restrictive" strategy for fluid administration has been shown to improve outcomes in certain groups of surgical patients. Whether a "restrictive" strategy can be used safely in high-risk patients using dobutamine to optimise cardiac function is not known.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics approval received from the local ethics committee (Comite de Etica em pesquisa da Faculdade de Medicina de Sao Jose do Rio Preto) on the 20th January 2006 (ref: 4361/2005).

Study design

Prospective randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Oxygen delivery in high-risk surgery

Interventions

Lithium indicator dilution and pulse power analysis is used to measure cardiac output and to calculate Oxygen Delivery Index (DO₂I) (LiDCO-plus system). A goal-directed therapy is used during surgery and eight-hours post-operatively aiming to maximise DO₂I to levels higher than 600 ml/min/m² using dobutamine and either "restrictive" (4 ml/kg/min) or "liberal" (12 ml/kg/min) strategies of intra-operative fluid management. Post-operatively both groups received 1.5 ml/kg/min of lactated ringer. Fluid challenge with 250 ml of colloid is given if there are signs of hypovolaemia.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Dobutamine

Primary outcome measure

Post-operative complications and hospital/Intensive Care Unit (ICU) length of stay.

Primary and secondary outcomes will be measured during the first interim analysis planned that will probably be done in around 2 months (according to the number planned in the project).

Secondary outcome measures

1. Perfusion variables (serum lactate, central venous oxygen saturation)
2. Organ dysfunction

Primary and secondary outcomes will be measured during the first interim analysis planned that will probably be done in around 2 months (according to the number planned in the project).

Overall study start date

20/02/2006

Completion date

20/02/2008

Eligibility**Key inclusion criteria**

1. Adult patients
2. Either major surgery and one clinical predictor of risk or intermediate risk surgery and the association of two clinical predictors (scoring system adapted from Shoemaker criteria/American College of Cardiology [ACC]/American Heart Association [AHA])

Participant type(s)

Patient

Age group

Adult

Sex

Not Specified

Target number of participants

116 patients (58 in each group). First analysis on 50% of the patients enrolled.

Total final enrolment

88

Key exclusion criteria

1. Emergency surgery
2. Acute myocardial ischaemia less than one month
3. Congestive heart failure (Functional Class IV New York Heart Association [NYHA])
4. Chronic renal failure (pre-operative creatinine greater than 2.0 mg/dl or need for dialysis)
5. Patients on lithium therapy
6. Severe arrhythmia

Date of first enrolment

20/02/2006

Date of final enrolment

20/02/2008

Locations**Countries of recruitment**

Brazil

Study participating centre

Av Faria Lima 5544

São José do Rio Preto

Brazil

15090-000

Sponsor information**Organisation**

Faculty of Medicine of Sao Jose do Rio Preto (FAMERP) Foundation (Brazil)

Sponsor details

Centro de Estudos e Pesquisa em Terapia Intensiva do Hospital de Base

c/o Professor Suzana Lobo

Av. Brigadeiro Faria Lima

5416 Vila Sao Pedro

Sao Jose do Rio Preto

Sao Paulo

Brazil

15091/000

Sponsor type

Hospital/treatment centre

Website

<http://www.famerp.br/>

ROR

<https://ror.org/052e6h087>

Funder(s)

Funder type

Hospital/treatment centre

Funder Name

Faculty of Medicine of Sao Jose do Rio Preto Foundation (Fundacao Faculdade de Medicina de Sao Jose do Rio Preto [FAMERP] - Hospital de Base) (Brazil)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/09/2011	31/12/2020	Yes	No